Ahead of print
Wytyczne / stanowisko ekspertów
Opublikowany online: 2022-12-12
Pobierz cytowanie

Postępowanie diagnostyczno-terapeutyczne u chorych na mięsaki kości — zalecenia ekspertów

Piotr Rutkowski1, Tomasz Świtaj1, Hanna Koseła-Paterczyk1, Daniel Kotrych2, Tomasz Goryń1, Tomasz Mazurkiewicz3, Jacek Fijuth4, Urszula Grzesiakowska1, Aneta Borkowska1, Mateusz Spałek1, Janusz Ryś5, Iwona Ługowska1, Anna Raciborska6, Andrzej Pieńkowski1, Bartłomiej Szostakowski1, Kamil Dolecki7, Michał Wągrodzki1, Urszula Grzesiakowska1, Tomasz Mandat1, Ewa Chmielik8, Marek Dedecjus1, Szymon Dragan9, Hanna Tchórzewska-Korba1
Afiliacje
  1. Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie — Państwowy Instytut Badawczy w Warszawie
  2. Pomorski Uniwersytet Medyczny w Szczecinie
  3. Uniwersytet Medyczny w Lublinie
  4. Zakład Radioterapii, Uniwersytet Medyczny w Łodzi
  5. Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie — Państwowy Instytut Badawczy, Oddział w Krakowie
  6. Instytut Matki i Dziecka w Warszawie
  7. Stowarzyszenie Pomocy Chorym na Mięsaki i Czerniaki SARCOMA
  8. Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie — Państwowy Instytut Badawczy, Oddział w Gliwicach
  9. Uniwersytet Medyczny we Wrocławiu

dostęp płatny

Ahead of print
WYTYCZNE POSTĘPOWANIA DIAGNOSTYCZNO-TERAPEUTYCZNEGO
Opublikowany online: 2022-12-12

Streszczenie

Brak

Streszczenie

Brak
Pobierz cytowanie

Słowa kluczowe

mięsak; kości; diagnostyka; terapia

Informacje o artykule
Tytuł

Postępowanie diagnostyczno-terapeutyczne u chorych na mięsaki kości — zalecenia ekspertów

Czasopismo

Onkologia w Praktyce Klinicznej - Edukacja

Numer

Ahead of print

Typ artykułu

Wytyczne / stanowisko ekspertów

Opublikowany online

2022-12-12

Wyświetlenia strony

80

Wyświetlenia/pobrania artykułu

55

Słowa kluczowe

mięsak
kości
diagnostyka
terapia

Autorzy

Piotr Rutkowski
Tomasz Świtaj
Hanna Koseła-Paterczyk
Daniel Kotrych
Tomasz Goryń
Tomasz Mazurkiewicz
Jacek Fijuth
Urszula Grzesiakowska
Aneta Borkowska
Mateusz Spałek
Janusz Ryś
Iwona Ługowska
Anna Raciborska
Andrzej Pieńkowski
Bartłomiej Szostakowski
Kamil Dolecki
Michał Wągrodzki
Urszula Grzesiakowska
Tomasz Mandat
Ewa Chmielik
Marek Dedecjus
Szymon Dragan
Hanna Tchórzewska-Korba

Referencje (76)
  1. Andritsch E, Beishon M, Bielack S, et al. ECCO Essential Requirements for Quality Cancer Care: Soft Tissue Sarcoma in Adults and Bone Sarcoma. A critical review. Crit Rev Oncol Hematol. 2017; 110: 94–105.
  2. Gerrand C, Athanasou N, Brennan B, et al. British Sarcoma Group. UK guidelines for the management of bone sarcomas. Clin Sarcoma Res. 2016; 6: 7.
  3. Casali PG, Bielack S, Abecassis N, et al. ESMO Guidelines Committee, PaedCan and ERN EURACAN. Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018; 29(Suppl 4): iv79–iv95.
  4. Wojciechowska U, Didkowska J. Zachorowania i zgony na nowotwory złośliwe w Polsce. Krajowy Rejestr Nowotworów, Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie — Państwowy Instytut Badawczy. http://onkologia.org.pl/raporty/ (27.03.2021).
  5. Lin PP, Patel S. Bone sarcoma. Springer 2013.
  6. Świtaj T, Nowecki Z. Mięsaki kości. In: Krzakowski M, Potemski P, Warzocha K, Wysocki P. ed. Onkologia kliniczna, tom 2. Via Medica, Gdańsk 2015.
  7. Kowalczyk J. Epidemiologia nowotworów dziecięcych. In: Kowalczyk J. ed. Wprowadzenie do onkologii i hematologii dziecięcej. CMKP, Warszawa 2011.
  8. Rutkowski P, Świtaj T, Mazurkiewicz T, et al. Bone sarcomas. Oncol Clin Pract. 2018; 14(3): 115–128.
  9. Grzesiakowska U. Radiologiczny atlas guzów kości. Medipage 2011.
  10. NCCN Clinical Practice Guidelines in Oncology 1.2022.
  11. Strauss SJ, Frezza AM, Abecassis N, et al. ESMO Guidelines Committee, EURACAN, GENTURIS and ERN PaedCan. Electronic address: clinicalguidelines@esmo.org. Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2021; 32(12): 1520–1536.
  12. WHO Classification of Tumours Editorial Board. Soft tissue and bone tumours., 5th edition 2020.
  13. Bovee J, Baumhoer D, Bloem JL, et al. Primary Tumour in Bone Histopathology Reporting Guide Biopsy Specimens. International Collaboration on Cancer Reporting; Sydney 2021. http://www.iccr-cancer.org/datasets/published-datasets/soft-tissue-bone.
  14. Protocol for the examination of specimens from patients with tumors of bone. Cancer protocol templates: www.cap.org. https://www.rcpath.org/resourceLibrary/dataset-for-histopathology-reports-on-primary-bone-tumours.html.
  15. American Joint Committee on Cancer. AJCC Cancer Staging Manual. 8th ed. American Joint Committee on Cancer, New York 2017.
  16. Gerrand C, Athanasou N, Brennan B, et al. British Sarcoma Group. UK guidelines for the management of bone sarcomas. Clin Sarcoma Res. 2016; 6: 7.
  17. Blay JY, Soibinet P, Penel N, et al. Improved survival using specialized multidisciplinary board in sarcoma patients. Ann Oncol. 2017; 28(11): 2852–2859.
  18. Whelan JS, Davis LE. Osteosarcoma, Chondrosarcoma, and Chordoma. J Clin Oncol. 2018; 36(2): 188–193.
  19. Brennan B, Kirton L, Marec-Bérard P, et al. Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial. Lancet. 2022; 400(10362): 1513–1521.
  20. Bacci G, Picci P, Ruggieri P. Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities. Cancer. 1990; 65: 2539–2553.
  21. Collins M, Wilhelm M, Conyers R, et al. Benefits and adverse events in younger versus older patients receiving neoadjuvant chemotherapy for osteosarcoma: findings from a meta-analysis. J Clin Oncol. 2013; 31(18): 2303–2312.
  22. Anninga JK, Gelderblom H, Fiocco M, et al. Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand? Eur J Cancer. 2011; 47(16): 2431–2445.
  23. Eilber F, Giuliano A, Eckardt J, et al. Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J Clin Oncol. 1987; 5(1): 21–26.
  24. Ferrari S, Smeland S, Mercuri M, et al. Italian and Scandinavian Sarcoma Groups. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol. 2005; 23(34): 8845–8852.
  25. Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002; 20(3): 776–790.
  26. Goorin AM, Harris MB, Bernstein M, et al. Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. J Clin Oncol. 2002; 20(2): 426–433.
  27. Navid F, Willert JR, McCarville MB, et al. Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma. Cancer. 2008; 113(2): 419–425.
  28. Huvos AG. Bone Tumours. Diagnosis, treatment and prognosis. 2nd edition. Bone-forming tumours: malignant 1991.
  29. Souhami RL, Craft AW, Van der Eijken JW, et al. Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet. 1997; 350(9082): 911–917.
  30. Jasnau S, Meyer U, Potratz J, et al. Cooperative Osteosarcoma Study Group COSS. Craniofacial osteosarcoma Experience of the cooperative German-Austrian-Swiss osteosarcoma study group. Oral Oncol. 2008; 44(3): 286–294.
  31. Frezza AM, Beale T, Bomanji J, et al. Is [F-18]-fluorodeoxy-D-glucose positron emission tomography of value in the management of patients with craniofacial bone sarcomas undergoing neo-adjuvant treatment? BMC Cancer. 2014; 14: 23.
  32. Marina NM, Smeland S, Bielack SS, et al. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. Lancet Oncol. 2016; 17(10): 1396–1408.
  33. Meyers PA, Schwartz CL, Krailo MD, et al. Children's Oncology Group. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group. J Clin Oncol. 2008; 26(4): 633–638.
  34. Riggi N, Suvà ML, Stamenkovic I. Ewing's Sarcoma. N Engl J Med. 2021; 384(2): 154–164.
  35. Cotterill SJ, Ahrens S, Paulussen M, et al. Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol. 2000; 18(17): 3108–3114.
  36. Nesbit ME, Gehan EA, Burgert EO, et al. Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long-term follow-up of the First Intergroup study. J Clin Oncol. 1990; 8(10): 1664–1674.
  37. Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med. 2003; 348(8): 694–701.
  38. Paulussen M, Craft AW, Lewis I, et al. European Intergroup Cooperative Ewing's Sarcoma Study-92. Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. J Clin Oncol. 2008; 26(27): 4385–4393.
  39. Le De, Paulussen M, Lewis I, et al. Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: results of the randomized noninferiority Euro-EWING99-R1 trial. J Clin Oncol. 2014; 32(23): 2440–2448.
  40. Brennan BKL, Marec-Berard P, et al. Comparison of two chemotherapy regimens in Ewing sarcoma (ES): Overall and subgroup results of the Euro Ewing 2012 randomized trial (EE2012). J Clin Oncol. 2020; 38(15_suppl): 11500–11500.
  41. Denbo JW, Shannon Orr W, Wu Y, et al. Timing of surgery and the role of adjuvant radiotherapy in ewing sarcoma of the chest wall: a single-institution experience. Ann Surg Oncol. 2012; 19(12): 3809–3815.
  42. Schuck A, Ahrens S, Paulussen M, et al. Local therapy in localized Ewing tumors: results of 1058 patients treated in the CESS 81, CESS 86, and EICESS 92 trials. Int J Radiat Oncol Biol Phys. 2003; 55(1): 168–177.
  43. Bacci G, Palmerini E, Staals EL, et al. Ewing's sarcoma family tumors of the humerus: outcome of patients treated with radiotherapy, surgery or surgery and adjuvant radiotherapy. Radiother Oncol. 2009; 93(2): 383–387.
  44. Ladenstein R, Pötschger U, Le Deley MC, et al. Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial. J Clin Oncol. 2010; 28(20): 3284–3291.
  45. Schuck A, Hofmann J, Rübe C, et al. Radiotherapy in Ewing's sarcoma and PNET of the chest wall: results of the trials CESS 81, CESS 86 and EICESS 92. Int J Radiat Oncol Biol Phys. 1998; 42(5): 1001–1006.
  46. Drabko K, Raciborska A, Bilska K, et al. Consolidation of first-line therapy with busulphan and melphalan, and autologous stem cell rescue in children with Ewing's sarcoma. Bone Marrow Transplant. 2012; 47(12): 1530–1534.
  47. Kim S, Ott HC, Wright CD, et al. Pulmonary resection of metastatic sarcoma: prognostic factors associated with improved outcomes. Ann Thorac Surg. 2011; 92(5): 1780–6; discussion 1786.
  48. Briccoli A, Rocca M, Salone M, et al. High grade osteosarcoma of the extremities metastatic to the lung: long-term results in 323 patients treated combining surgery and chemotherapy, 1985-2005. Surg Oncol. 2010; 19(4): 193–199.
  49. Spałek MJ, Poleszczuk J, Czarnecka AM, et al. Radiotherapy in the Management of Pediatric and Adult Osteosarcomas: A Multi-Institutional Cohort Analysis. Cells. 2021; 10(2).
  50. Grignani G, Palmerini E, Ferraresi V, et al. Italian Sarcoma Group. Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. Lancet Oncol. 2015; 16(1): 98–107.
  51. Davis LE, Bolejack V, Ryan CW, et al. Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma. J Clin Oncol. 2019; 37(16): 1424–1431.
  52. Duffaud F, Mir O, Boudou-Rouquette P, et al. French Sarcoma Group. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol. 2019; 20(1): 120–133.
  53. Ferrari S, Briccoli A, Mercuri M, et al. Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival. J Clin Oncol. 2003; 21(4): 710–715.
  54. Palmerini E, Torricelli E, Cascinu S, et al. Is there a role for chemotherapy after local relapse in high-grade osteosarcoma? Pediatr Blood Cancer. 2019; 66(8): e27792.
  55. Palmerini E, Jones RL, Marchesi E, et al. Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone. BMC Cancer. 2016; 16: 280.
  56. Raciborska A, Bilska K, Drabko K, et al. Vincristine, irinotecan, and temozolomide in patients with relapsed and refractory Ewing sarcoma. Pediatr Blood Cancer. 2013; 60(10): 1621–1625.
  57. Whelan JS, Burcombe RJ, Janinis J, et al. A systematic review of the role of pulmonary irradiation in the management of primary bone tumours. Ann Oncol. 2002; 13(1): 23–30.
  58. Raciborska A, Bilska K, Rychłowska-Pruszyńska M, et al. Management and follow-up of Ewing sarcoma patients with isolated lung metastases. J Pediatr Surg. 2016; 51(7): 1067–1071.
  59. Dierselhuis EF, Goulding KA, Stevens M, et al. Intralesional treatment versus wide resection for central low-grade chondrosarcoma of the long bones. Cochrane Database Syst Rev. 2019; 3: CD010778.
  60. Weber DC, Rutz HP, Pedroni ES, et al. Results of spot-scanning proton radiation therapy for chordoma and chondrosarcoma of the skull base: the Paul Scherrer Institut experience. Int J Radiat Oncol Biol Phys. 2005; 63(2): 401–409.
  61. DeLaney TF, Liebsch NJ, Pedlow FX, et al. Long-term results of Phase II study of high dose photon/proton radiotherapy in the management of spine chordomas, chondrosarcomas, and other sarcomas. J Surg Oncol. 2014; 110(2): 115–122.
  62. Igaki H, Tokuuye K, Okumura T, et al. Clinical results of proton beam therapy for skull base chordoma. Int J Radiat Oncol Biol Phys. 2004; 60(4): 1120–1126.
  63. Noël G, Feuvret L, Calugaru V, et al. Chordomas of the base of the skull and upper cervical spine. One hundred patients irradiated by a 3D conformal technique combining photon and proton beams. Acta Oncol. 2005; 44(7): 700–708.
  64. Ares C, Hug EB, Lomax AJ, et al. Effectiveness and safety of spot scanning proton radiation therapy for chordomas and chondrosarcomas of the skull base: first long-term report. Int J Radiat Oncol Biol Phys. 2009; 75(4): 1111–1118.
  65. DeLaney TF, Liebsch NJ, Pedlow FX, et al. Phase II study of high-dose photon/proton radiotherapy in the management of spine sarcomas. Int J Radiat Oncol Biol Phys. 2009; 74(3): 732–739.
  66. Rutz HP, Weber DC, Sugahara S, et al. Extracranial chordoma: Outcome in patients treated with function-preserving surgery followed by spot-scanning proton beam irradiation. Int J Radiat Oncol Biol Phys. 2007; 67(2): 512–520.
  67. Zabel-du Bois A, Nikoghosyan A, Schwahofer A, et al. Intensity modulated radiotherapy in the management of sacral chordoma in primary versus recurrent disease. Radiother Oncol. 2010; 97(3): 408–412.
  68. Stacchiotti S, Sommer J. Chordoma Global Consensus Group. Building a global consensus approach to chordoma: a position paper from the medical and patient community. Lancet Oncol. 2015; 16(2): e71–e83.
  69. Demizu Y, Imai R, Kiyohara H, et al. Japan Carbon-Ion Radiation Oncology Study Group. Carbon ion radiotherapy for sacral chordoma: A retrospective nationwide multicentre study in Japan. Radiother Oncol. 2021; 154: 1–5.
  70. DeLaney TF, Liebsch NJ, Pedlow FX, et al. Long-term results of Phase II study of high dose photon/proton radiotherapy in the management of spine chordomas, chondrosarcomas, and other sarcomas. J Surg Oncol. 2014; 110(2): 115–122.
  71. Agencja Oceny Technologii Medycznych i Taryfikacji. Rekomendacja nr 85/2015 z dnia 29 października 2015 r. Prezesa Agencji Oceny Technologii Medycznych i Taryfikacji w sprawie zakwalifikowania świadczenia opieki zdrowotnej „Radioterapia protonowa nowotworów zlokalizowanych poza narządem wzroku” jako świadczenia gwarantowanego z zakresu leczenia szpitalnego. www.aotmit.gov.pl.
  72. Frezza AM, Botta L, Trama A, et al. Chordoma: update on disease, epidemiology, biology and medical therapies. Curr Opin Oncol. 2019; 31(2): 114–120.
  73. Ruka W, Rutkowski P, Morysiński T, et al. The megavoltage radiation therapy in treatment of patients with advanced or difficult giant cell tumors of bone. Int J Radiat Oncol Biol Phys. 2010; 78(2): 494–498.
  74. Chawla S, Henshaw R, Seeger L, et al. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol. 2013; 14(9): 901–908.
  75. Rutkowski P, Gaston L, Borkowska A, et al. Denosumab treatment of inoperable or locally advanced giant cell tumor of bone - Multicenter analysis outside clinical trial. Eur J Surg Oncol. 2018; 44(9): 1384–1390.
  76. Rutkowski P, Ferrari S, Grimer RJ, et al. Surgical downstaging in an open-label phase II trial of denosumab in patients with giant cell tumor of bone. Ann Surg Oncol. 2015; 22(9): 2860–2868.

Regulamin

Ważne: serwis https://journals.viamedica.pl/ wykorzystuje pliki cookies. Więcej >>

Używamy informacji zapisanych za pomocą plików cookies m.in. w celach statystycznych, dostosowania serwisu do potrzeb użytkownika (np. język interfejsu) i do obsługi logowania użytkowników. W ustawieniach przeglądarki internetowej można zmienić opcje dotyczące cookies. Korzystanie z serwisu bez zmiany ustawień dotyczących cookies oznacza, że będą one zapisane w pamięci komputera. Więcej informacji można znaleźć w naszej Polityce prywatności.

Czym są i do czego służą pliki cookie możesz dowiedzieć się na stronie wszystkoociasteczkach.pl.

 

Wydawcą serwisu jest  VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl